At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|March 6, 2023
Yale student discusses findings of disparities among patients with prostate cancer
Author(s)Urology Times staff
"We also saw in the high-risk group that patients who identified as Black were much more likely to not receive treatment than their White counterparts," says Madison Novosel, BA.
Advertisement
In this video, Madison Novosel discusses notable findings from her thesis project, “Associations between patient sociodemographic factors and non-treatment for localized prostate cancer”, which were presented at the 2023 American Society of Clinical Oncology
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5